- ►nih.gov R Abdi, P Fiorina, CN Adra, M Atkinson, MH … - Diabetes, 2008 - Am Diabetes Assoc Mesenchymal stem cells (MSCs) are pluripotent stromal cells that have the
potential to give rise to cells of diverse lineages. Interestingly, MSCs can be
found in virtually all postnatal tissues. The main criteria currently used ... Cited by 20 - Related articles - All 11 versions
K Ozaki, K Sato, I Oh, A Meguro, R Tatara, K … - International journal of hematology, 2007 - Springer Abstract Mesenchymal stem cells (MSCs) have been identified in animals,
especially in bone marrow. As stem cells, they have the ability to differentiate
into multiple cell types.This potential raises exciting therapeutic ... Cited by 6 - Related articles - BL Direct - All 3 versions
PR Koppula, LK Chelluri, N Polisetti, GK … - Cellular Immunology, 2009 - Elsevier Mesenchymal stem cells (MSCs) lack major histocompatibility complex (MHC)-II and
only show minimal MHC-I expression. Despite MSCs demonstrating T-cell anergy,
there are no established methods to evaluate their suitability. It is ... Related articles - All 2 versions
AM Madec, R Mallone, G Afonso, E Abou Mrad, … - Diabetologia, 2009 - Springer Abstract Aims/hypothesis Displaying immunomodulatory capacities, mesenchymal
stem cells (MSCs) are considered as benefi- cial agents for autoimmune diseases.
The aim of this study was to examine the ability of MSCs to prevent ... Cited by 1 - Related articles - All 2 versions
AE Aksu, E Horibe, J Sacks, R Ikeguchi, J … - Clinical Immunology, 2008 - Elsevier We investigated the effect of autologous mesenchymal stem cells (MSC) on
multiple unmodified donor bone marrow (BM) infusions and vascularized skin graft
outcome. BM-derived rat MSC were examined for phenotype and function. ... Cited by 12 - Related articles - All 3 versions
[CITATION] von HM (2007) Translational mini-review series on type 1 diabetes: Immune-based …
- ►diabetesjournals.org Y Huang, IJ Fugier-Vivier, T Miller, MJ Elliott, … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—We report for the first time that NOD FCs are functionally impaired.
They fail to facilitate engraftment of syngeneic and allogeneic HSCs in vivo and
do not enhance HSC clonogenicity in vitro. NOD FCs contain subpopulations ... Cited by 2 - Related articles - All 5 versions
Y Jin, X Chen, R Podolsky, D Hopkins, LHC … - Clinical Immunology, 2009 - Elsevier It is widely believed that CD4 + CD25 + regulatory T cells (Treg) are defective
in type 1 diabetes (T1D) and other autoimmune diseases. However, this conclusion
is based on the suboptimal in vitro suppression results from very small ... Cited by 2 - Related articles - All 2 versions
[CITATION] Frequancy of HLA class II DR and DQ in Brazilian patients with type I diabetes
C Ricordi, BJ Hering, AMJ Shapiro - The Lancet, 2008 - Elsevier Islet transplantation outcomes are likely to improve substantially over the next
3–5 years, as a result of novel immunosuppressive regimens with fewer toxic
effects. Even more far-reaching improvements will emerge from islet ... Cited by 3 - Related articles - All 9 versions
